We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the...
Read ArticleBotanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have...
Read ArticleASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleOrthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US...
Read ArticleOrthocell (ASX:OCC) has announced its receipt of commitments for $17M in funding via placement to ba...
Read ArticleASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappoint...
Read ArticleThe nerve-repair company’s shares have been on a tear after a series of positive regulatory and oper...
Read ArticleHighlights ASX200 index falls 1.66% in its worst day in seven weeks. Health Care sector tak...
Read ArticleThe ASX200 closed down 1.66% at 8,205 points in its worst day in seven weeks. The local bourse sh...
Read ArticleEBR has developed the WiSE Cardiac Resynchronization Therapy (CRT) system, the world’s first leadle...
Read ArticleStockhead’s Sarah Hughan sits down with Orthocell’s (ASX:OCC) CEO and MD Paul Anderson to get the sh...
Read ArticleSingapore’s medical regulator this week approved Orthocell’s leading nerve-repair device Remplir...
Read ArticleShares in regenerative medicine company Orthocell soared after the company received regulatory appro...
Read ArticleHighlights ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell as China shifted focu...
Read ArticleThe ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn in...
Read ArticleWest Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approva...
Read ArticleOrthocell gains regulatory approval from Singapore’s Health Sciences Authority for its nerve repair...
Read ArticleOrthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million...
Read ArticleOrthocell achieves a second consecutive quarter of record revenue, reporting $2.03m in Q1 FY25 Rev...
Read ArticleASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition...
Read ArticleMesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleSoutheast Asia presents growth for ASX health stocks with rising aging population and growing middl...
Read ArticleThe ASX200 closed up 0.39% at 8,013 points. The bank stocks rallied leading the index higher, but...
Read ArticleWA regenerative medicine company Orthocell has started selling its dental bone repair product in Can...
Read ArticleThe ASX200 has been up around 0.5% at 8,025 points. Bank stocks have surged and dragged the marke...
Read ArticleStockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episod...
Read ArticleOrthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product St...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleStockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chair John Van Der Wielen to get the sho...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleSeveral ASX healthcare companies are proudly manufacturing products in Australia Polynovo, Optisca...
Read ArticleWestern Australia wanting to diversity beyond resources and become a global leader in health and me...
Read ArticleThe 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on...
Read ArticleShares in WA regenerative medicine company Orthocell are up after it received regulatory approval to...
Read ArticleThe ASX200 had a strong day closing up 0.93%. All sectors closed in the green with top performer ...
Read ArticleASX 200 punches it, record highs back in view 11 of 11 sectors higher, like a well-oiled machine...
Read ArticleOrthocell receives regulatory approval to sell dental guided bone regeneration product Striate+ i...
Read ArticleASX 200 closes 0.16pc lower after modest rally from morning lows Six of 11 sectors lower, after r...
Read ArticleASX 200 rises strongly on Tuesday, closes up +0.86pc All 11 sectors in the green, like Kermit on...
Read ArticleSpecial Report: Dropping milestone numbers this week is the Perth-based regenerative medtech Ortho...
Read ArticleOrthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged re...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleAussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sector...
Read ArticleOrthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft p...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleWA regenerative medicine company Orthocell has reported a near 100 per cent success rate for its den...
Read ArticleRace Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThe ASX200 closed around a quarter of a per cent up with Consumer discretionary topping the gains, f...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Rempli...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticlePerth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up o...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed...
Read ArticleRegenerative medicine company Orthocell says it has successfully completed the first stage of a pivo...
Read ArticleArgenica granted US FDA’s Rare Pediatric Disease Designation Orthocell completes Remplir study, tar...
Read ArticleBiotech tends to follow a four to five year market cycle and those in the sector say there are signa...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleThe $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and...
Read ArticleLocal markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat The ASX200...
Read ArticleOrthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoA...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleIn drug development there’s a narrow window to get to market and long delays tend to be fatal – and...
Read ArticlePerth-based regenerative medicine company Orthocell has appointed famed plastic surgeon Fiona Wood t...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleOrthocell’s sales ramped up in three months to June with the Perth-based regenerative medicine compa...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wiel...
Read ArticleOrthocell has launched a new bio-manufacturing facility in what boss Paul Anderson said represented...
Read ArticlePfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of...
Read ArticleThe Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleThe Australian share market dipped on Tuesday, with the benchmark ASX 200 index down nearly 20 point...
Read ArticleNeuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study...
Read ArticleOrthocell (OCC) kicks off a ‘comparator’ study as part of its pre-clinical and clinical development...
Read ArticleLabor has announced that if elected it will launch a $38 million expansion of Australia's ne...
Read ArticleOrthocell (OCC) appoints internationally-recognised nerve surgeons Professor Christopher Dy and Prof...
Read ArticleTelehealth specialist Global Health signs partnership deal with Woolworths subsidiary The deal will...
Read ArticleOrthocell says a $23 million manufacturing deal for its product has put the regenerative medicine co...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleSurgeons can now be reimbursed for the use of Orthocell’s nerve-reconstruction device SaaS player R...
Read ArticleOrthocell’s (OCC) Remplir product is included on the Australian Prostheses ListThe company says incl...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced that its Remplir has been ad...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleShareCafeRebound rally: Aus shares close 1.4 per cent higher by Lauren Hayes The S&P/ASX 200 e...
Read ArticleOrthocell (OCC) reports positive results from its crossover patient extension arm of its rotator cuf...
Read ArticleShareCafeResurgent ASX rallies: Aus shares 1.8% higher at noon By Lauren Hayes At noon, the S&...
Read ArticleNasdaq-listed Biogen says its experimental Alzheimer’s drug study was successful The news sends ASX...
Read ArticleThe ASX will open much higher on Thursday Wall Street rallied strongly overnight as yields slump fo...
Read ArticlePYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical...
Read ArticleOrthocell (OCC) receives its first purchase orders for its Striate+ and Remplir products from partne...
Read ArticleOrthocell (OCC) appoints an exclusive Australian distributor for RemplirThe company penned a distrib...
Read ArticlePerth-based regenerative medicine company Orthocell has inked a new deal with Device Technologies to...
Read ArticleASX 200 drops load circa 1430 (AEST) ends 0.4% lower Small caps index laughs openly in face of dan...
Read ArticleDR BOREHAM’S CRUCIBLE: ORTHOCELL Market cap: $74.9m Shares on issue: 197,127,913 Chief executive off...
Read ArticleShareCafeEvening Report: 21 July, 2022 by Paul Sanger At the closing bell, the S&P/ASX 200 was...
Read ArticleOrthocell (OCC) takes the next steps in its license and distribution agreements for its Striate+ de...
Read ArticleShareCafeLunch Report: 21 July, 2022 by Paul Sanger Australian shares are little changed in mixed...
Read ArticleShareCafeStocks of the Hour: 21 July, 2022 Orthocell (ASX:OCC) recently signe...
Read Article21 Jul 2022 - A snapshot of the stocks on the move featuring Orthocell (ASX:OCC), Telix Pharmaceutic...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleShareCafeOrthocell (ASX: OCC) – Webinar presentation Paul Anderson – Managing DIrector – Orthocell...
Read ArticleShareCafeWebinar Recap – PCK, OCC, LCL & ICE Catch up on the full webinar presentations from Pa...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleThe ASX200 makes it four gains in a row The small cap index remains uninspired despite some strong...
Read ArticleShares in regenerative medicine company Orthocell are flying after it signed a licencing and manufac...
Read ArticleOrthocell jumps 35% after signing global license deal Imricor in with Siemens deal on 3D imaging sy...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has entered into an exclusive patent and t...
Read ArticleIt wasn’t exactly a red-letter day for the market as a whole, though – the ASX adding less than 0.5%...
Read ArticleAvita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is pop...
Read ArticleOrthocell’s (OCC) nerve reconstruction trial demonstrates the early recovery of muscle function in...
Read ArticleOrthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approv...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleManaging director Paul Anderson said, “Remplir is the first of its kind biological scaffold...
Read ArticleRegenerative medicine company Orthocell (OCC) receives regulatory approval for its Remplir peripher...
Read ArticleOrthocell’s Remplir device gets approval for the Australian Register of Therapeutic Goods (ARTG) Ar...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has provided a US market entry update for...
Read ArticleOrthocell (OCC) is set to scale up the manufacturing capacity of its Striate+ premium dental membra...
Read ArticleIt has also received approvals to upgrade its existing facility and scale-up Striate+™ manufacturing...
Read ArticleThe company is focused on regenerating mobility for patients by developing innovative products for t...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read Article“This is exciting research that opens up potential for novel treatments addressing significant unmet...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleUltimately, the new data supports the breadth of Orthocell’s cornerstone CelGro™ platform, with posi...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleThe ASX had another day of solid gains, hitting a three week high with tech and resources leading th...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success....
Read ArticleThe orthopaedic cell therapy company is in its strongest position yet to launch into the lucrative U...
Read ArticleOrthocell’s (OCC) latest study results reveal OrthoATI is more effective than steroid injection for...
Read ArticleThe ASX finished 0.67% higher, marking the best performance by the Australian bourse since early Oct...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced that the Autologous Tenocyte...
Read Article“This is an important development milestone for OrthoATI® and the company and I am delighted to have...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index w...
Read ArticleIn October, the Chinese government released its intellectual proprietary (IP) patents strategy paper...
Read ArticleTurn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but...
Read ArticleOrthocell’s CelGro platform forms the basis of a specialised collagen ‘rope’ that could help reconst...
Read ArticleThe biggest director trade on the ASX in the past fortnight came from one of Australia’s most famous...
Read ArticleThe regenerative medicine company could be on the verge of developing the first off-the-shelf biolog...
Read ArticleThe ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the br...
Read ArticleHighlights The ASX 200 closed marginally higher on Tuesday despite the Reserve Bank of Australi...
Read ArticleThe company’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior...
Read ArticleHighlights The ASX 200 was trading flat at 7,536.9 by lunchtime. A-VIX, which shows the volatil...
Read ArticleShareCafeAustralia… One Hour In… ASX200 down 74 ASX200 down 24 points (0.3%) to 7504. Reserve Bank...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced that new patents have been g...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced that the last patient in the...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read Article“This is an important development milestone for Ortho-ATI and the company, representing the first ra...
Read ArticleThe regenerative medicine company focused on advancing its CelGro® and Ortho-ATI® pipelines during F...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleLocal markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday a...
Read ArticleThe findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic gra...
Read ArticleThe biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that...
Read ArticleThe ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting it...
Read ArticleThe ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting it...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSummary Kirkland (ASX:KLA) reports record production in second quarter 2021 Finbar (ASX:FRI) ri...
Read ArticleThe company believes SMT is the ideal partner for the Australian market, with its established relati...
Read ArticleShares in Perth-based regenerative medicine company Orthocell are climbing on news it has appointed...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced the first interim...
Read ArticleTwelve months on from Orthocell’s CelGro® nerve regeneration trial, a data readout has indicated mor...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is gaining in morning trade, up 3.3%. Below we take a look...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand pate...
Read ArticleSummary Commonwealth Bank (ASX:CBA) sets new high, adds nearly A$7 billion in value over 3 week...
Read ArticleSummary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. Th...
Read ArticleThe patents cover the method of using CelGro® to repair a defect in soft tissue, such as tendons, li...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it’s at 57.5 ce...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleA recent article published in the Advance Science magazine discussed research by Monash University t...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced Chinese and Hong Kong patent...
Read ArticleChina and Hong Kong have granted patents to the product, which is used to augment ligament repair su...
Read ArticleChina and Hong Kong have granted patents to the product, which is used to augment ligament repair su...
Read ArticleOrthocell is well-positioned to establish CelGro® as the best-in-class membrane for bone and soft ti...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced what it describes as positiv...
Read ArticleSummary Regenerative medicine player Orthocell has announced positive results from the US 510(k)...
Read ArticleThe breakthrough results position CelGro® as the potential market leader in nerve regeneration and r...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is rising today following news of a successful pilot anima...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced it has received notification...
Read ArticleSource:Phongphan ,Shutterstock ASX 200 has held its gains in the afternoon today. Australian bond y...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is edging higher today following the inclusion of CelGro D...
Read ArticleSource: Voronin76,Shutterstock Summary World-leading regenerative medicine company Orthocell re...
Read ArticleThe prostheses list defines the minimum value of benefit private insurers pay for CelGro® Dental use...
Read ArticleSource: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic,...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has been granted a new US metho...
Read ArticleSummary World-leading regenerative medicine player Orthocell Limited has obtained US patent for...
Read ArticleSummary ASX shares have been on an upward swing on Monday. The benchmark index rose sharply sinc...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price has had a mixed day of trading so far after the company an...
Read ArticlePatents for CelGro® have previously been granted in the US, Canada, Europe, China, Japan, Singapore,...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) says its 'Striate +' produce ha...
Read ArticleOrthocell Ltd (ASX: OCC) shares are edging higher in mid-afternoon trade after the company announce...
Read ArticleThe Prosthesis list defines the minimum amount of benefit to be paid by private insurers for CelGro®...
Read ArticleCelGro represents a breakthrough in soft tissue reconstruction and offers commercial potential in ex...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced the publication o...
Read ArticlePerth-based regenerative medicines outfit Orthocell has developed a biological collage membrane devi...
Read ArticleThe case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced it has received an R&D T...
Read ArticleThe funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair...
Read ArticleDrug development is a long and tedious process, often taking years to reach commercialisation. Small...
Read ArticleSummary ASX 200 recovered after slipping in the early trade, with healthcare and technology sect...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is one of the best performers on the market today. This co...
Read ArticleUS market clearance provides a pathway for OCC to continue driving the development of CelGro collage...
Read ArticleUS market clearance provides a pathway for OCC to continue driving the development of CelGro collage...
Read ArticleSummary Orthocell has received FDA 510(k) clearance to market and supply its CelGro device in th...
Read ArticleThe company recently received the green light to introduce its CelGro® collagen medical device into...
Read ArticleSummary Regenerative medicine company Orthocell receives market approval for its collagen medica...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is surging higher today. This comes after the biotechnolog...
Read ArticleThe approval positions Orthocell well for US Food and Drug Administration (FDA) approval, targeted f...
Read ArticleASX-listed regenerative medicine player Orthocell Limited (ASX:OCC) announced a major achievement to...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is edging higher today. This comes after the company annou...
Read ArticleThe company has successfully completed the Australian TGA Conformity Assessment process around the s...
Read ArticleSummary Regenerative medicine company Orthocell Limited released positive results in its CelGro®...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is 17% higher this morning, after the company released pos...
Read ArticleOrthocell’s (ASX:OCC) latest clinical study results led to shares rising more than 20 per cent this...
Read ArticleThe regenerative medicine company is now progressing regulatory applications in Australia and will s...
Read ArticleThe paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ rep...
Read ArticleThe paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ rep...
Read ArticleThe company’s portfolio of regenerative medicine products have shown in clinical studies and real wo...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced the publication of positive...
Read ArticleThe SAS product use also provides real-world evidence for the safety and efficacy of CelGro®, furthe...
Read ArticleThe company is well-positioned to establish its CelGro® product as the best-in-class membrane for bo...
Read ArticleThe company’s commercialisation strategy for the product will leverage the TGA results for regulator...
Read ArticleThe trademark will remain in force for an initial period of 10 years and may be renewed for successi...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe study captures patient feedback/outcomes for reduction of pain, functional improvement and overa...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced the completion of...
Read ArticleThe companies will begin the trial to assess the effectiveness of Ortho-ATI, a novel cell therapy d...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced the appointment of Leslie Wi...
Read ArticleWith a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is we...
Read ArticleThe therapy features in a chapter of the book which has been downloaded more than 3,000 times.
Read ArticleA 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as s...
Read ArticlePharmAust (ASX:PAA) shares surged this morning on news a clinical trial of its drug that fights canc...
Read ArticleWould you have invested in Amazon in the 90s, when it was a scrappy startup exploiting this new thin...
Read ArticleDuring the quarter, the company continued its clinician advocacy program to expand the network of re...
Read ArticleThe announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders b...
Read ArticleThe regenerative medicine company is focused on regenerating mobility for patients by developing pro...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced positive results...
Read ArticleRegenerative medicine company Orthocell (ASX: OCC) has completed a US FDA regulatory study demonstra...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAs with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time atta...
Read ArticleLast week markets had their worst week since the global financial crisis (GFC) and the carnage, at l...
Read ArticleShareCafeAll The Dope On Emerald Clinics’ Limp Debut Having been long on promises but short on deliv...
Read ArticleWith the health and life science sector being the ASX’s top performer last year, Western Australia i...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced it has been granted Canadian...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has reported a Research and Development (R...
Read ArticleThe European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead mol...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleWho said you have to be patient to net a hefty return on an investment? There are 10 ASX small caps...
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) says it has received confirmation from the...
Read ArticlePharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good o...
Read ArticleSmall-cap biotech company Orthocell Ltd [ASX:OCC] has entered a trading halt today. A request that w...
Read ArticleIt can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve smal...
Read ArticleRegenerative medicine company Orthocell (ASX: OCC) has been granted a key patent for a 16-year perio...
Read ArticleOrthocell (ASX:OCC) has found a new use for its CelGro tech – anterior cruciate ligament (ACL) injur...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBi...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleBotanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical t...
Read ArticleSpecial Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 gue...
Read ArticleOn Stockhead today: gold is good, but which miners offer the best returns, how ASX pot stocks are ma...
Read ArticleOn Wednesday, small cap ASX biotech Orthocell (ASX:OCC) reported that its collagen scaffold technolo...
Read ArticleThe Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicin...
Read ArticleAussie biotech Orthocell Ltd [ASX:OCC] has seen a magnificent spike in their share price today, up a...
Read ArticleRegenerative medicine company Orthocell (ASX: OCC) came out of a trading halt this morning with posi...
Read ArticleAustralian regenerative medicine company Orthocell (ASX:OCC) has announced positive interim...
Read ArticleOn Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intrigu...
Read ArticleOn Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s t...
Read ArticleIn 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks...
Read ArticleThe WA investment community will turn its attention to healthcare next Thursday, when the annual Bio...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleShares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, curr...
Read ArticleFollow-up results from a CelGro tendon regeneration clinical trial conducted by Perth-based regenera...
Read Article04 Sep 2019 - Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patie...
Read ArticleShares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced a Japanese patent for CelGro...
Read ArticleThe collagen ropes enhance soft tissue repairs to areas such as anterior cruciate ligaments or ACLs.
Read ArticleThe healthcare industry of Australia is a key contributor in developing the economy. The companies w...
Read ArticleWe’ve been pondering the next recession since the GFC. There have been warning signs, in 2011, 2015,...
Read ArticleThe pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven indust...
Read ArticleRemember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro help...
Read ArticleOrthocell (ASX: OCC) published yet another batch of trial results relating to CelGro which it says v...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleRegenerative medicine company Orthocell (ASX:OCC) has announced positive pre-clinical result...
Read ArticleWhen your stock crashes you have three options: run away (and wait to claim the tax loss), sit still...
Read ArticleHere’s one that investors can really get their teeth into: Orthocell’s (ASX:OCC) regenerative therap...
Read ArticleAt Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its...
Read ArticleThe Australian economy, like many countries, is facing challenges in terms of an ageing population,...
Read ArticleThe positive data comes as Orthocell is active in partnering discussions and will support the compan...
Read ArticleCV Check Ltd CV Check Ltd (ASX: CV1) is a leading online integrated screening and verification compa...
Read ArticleOrthocell (ASX: OCC) has achieved a substantial reduction in dental implant treatment timeframes dur...
Read ArticleShares in grow-your-own-bone biotech Orthocell (ASX:OCC) are up after it proved, once again, that we...
Read ArticleIt’s only a couple of weeks until the end of financial year and some people take steps to minimise t...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
